Past Most cancers ™ Proclaims the Appointment of Jedidiah Monson, MD to Chief Medical Officer

Past Air ™ Dr. Monson is a board-certified radiation oncologist and brings over 25 years

Past Air ™

Dr. Monson is a board-certified radiation oncologist and brings over 25 years of medical oncology expertise to Past Most cancers.

Dr. Monson is a founding accomplice and President of California Most cancers Associates for Analysis & Excellence (cCARE), the biggest non-public oncology apply in California.

HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) – Past Most cancers, Ltd., an affiliate of Past Air, Inc. (NASDAQ: XAIR) that’s centered on creating ultra-high focus nitric oxide (UNO) for the remedy of strong tumors, immediately introduced the appointment of Jedidiah Monson, MD to the place of Chief Medical Officer, efficient June 1, 2022.

“We’re excited to nominate Dr. Monson as our Chief Medical Officer at this vital level within the brief historical past of Past Most cancers. On this function, he’ll oversee our first-in-human trial in Israel, which is predicted to start by mid-2022, in addition to spearhead our efforts to start medical trials within the US, ”commented Selena Chaisson, CEO of Past Most cancers . “Dr. Monson’s contributions to the sphere of oncology and to sufferers at a prestigious medical care and analysis centered establishment will likely be a useful useful resource for Past Most cancers as we proceed our mission of bringing ultra-high focus nitric oxide (UNO) remedy to strong tumor sufferers. ”

“The idea of nitric oxide utilized at ultra-high concentrations to impart an immune response with probably minimal unwanted side effects is an thrilling prospect. The preclinical knowledge offered by Past Most cancers to this point have proven UNO remedy has the potential to be an important remedy choice for most cancers sufferers and their caregivers, ”commented Dr. Monson on his appointment as Chief Medical Officer. “I’m excited to hitch Past Most cancers as we glance to start enrolling sufferers in a first-in-human medical trial.”

Dr. Monson, a founding accomplice of cCARE in 2008, oversaw its development into the biggest non-public apply oncology group within the state of California with a deal with analysis and excellence in medical care. In April 2022, cCARE merged with Built-in Oncology Community (ION) leading to a nationwide oncology and healthcare administration group, with a presence in 57 oncology facilities throughout 14 states. He has beforehand held workers positions on the Metropolis of Hope Nationwide Medical Heart, Valley Radiotherapy Associates, and 21st Century Oncology. As well as, Dr. Monson is a member of the American Faculty of Radiology and the American Society of Therapeutic Radiology & Oncology.

See also  Challenge Volterra: Microsoft Pronounces Home windows 11 on ARM Developer Equipment with a Snapdragon SoC

Dr. Monson earned his MD from Stanford College Faculty of Medication and accomplished his radiation oncology residency on the Joint Heart for Radiation Remedy at Harvard Medical Faculty. Throughout his residency, he acquired an MPH from Harvard Faculty of Public Well being.

About Nitric Oxide (NO)

Nitric Oxide (NO) is a robust molecule, naturally synthesized within the human physique, confirmed to play a important function in a broad array of organic features. At the moment, exogenous inhaled NO is utilized in grownup respiratory misery syndrome, put up sure cardiac surgical procedures, and protracted pulmonary hypertension of the new child to deal with hypoxemia. Moreover, NO is believed to play a key function within the innate and adaptive immune system response and in vitro research recommend that NO possesses broad-spectrum antimicrobial exercise and anticancer properties.

About Past Most cancers, Ltd.

Past Most cancers, Ltd., an affiliate of Past Air, Inc., is a development-stage biopharmaceutical and medical gadget firm using ultra-high focus nitric oxide (UNO) through a proprietary supply platform to deal with main tumors and stop metastatic illness. Nitric oxide at ultra-high concentrations has been reported to point out anticancer properties and to probably function a chemosensitizer and radiotherapy enhancer. The Firm is at the moment conducting preclinical research of UNO in a number of strong tumors to tell remedy protocols. Primarily based on its present findings, Past Most cancers is predicted to start a first-in-human medical trial in unresectable strong main or metastatic tumors this yr. For extra info, go to

About UNO Remedy for Strong Tumors

See also  Acer Pronounces New Predator Gaming Laptops, Chromebooks, and Extra; Listed here are the Particulars!

Most cancers is the second main reason behind dying globally, with tumor metastases chargeable for roughly 90% of all cancer-related deaths. Present most cancers remedy modalities usually embrace chemotherapy, immunotherapy, radiation, and / or surgical procedure. Extremely-high focus Nitric Oxide (UNO) remedy is a totally new strategy to stopping relapse or metastatic illness. In vitro murine knowledge present that native tumor ablation with UNO stimulates an antitumor immune response in strong tumor most cancers fashions. UNO has the potential to stop relapse or metastatic illness with as little as a single 5-minute remedy and with restricted toxicity or off-target results.

About Past Air, Inc.

Past Air, Inc. (NASDAQ: XAIR) is a clinical-stage medical gadget and biopharmaceutical firm creating a revolutionary NO Generator and Supply System, LungFit®, that makes use of NO generated from ambient air to ship exact quantities of NO to the lungs for the potential remedy of quite a lot of pulmonary ailments. The LungFit® can generate as much as 400 ppm of NO, for supply both repeatedly or for a set period of time and has the power to both titrate dose on demand or preserve a continuing dose. The corporate is at the moment making use of its therapeutic experience to develop remedies for pulmonary hypertension in varied settings, along with remedies for respiratory tract infections that aren’t successfully addressed with present requirements of care. Past Air is at the moment advancing its revolutionary LungFit® for medical trials for the remedy of extreme lung infections comparable to acute viral pneumonia (together with COVID-19) and nontuberculous mycobacteria (NTM). Moreover, Past Air, by its affiliate Past Most cancers, Ltd., is utilizing ultra-high concentrations of NO with a proprietary supply system to focus on sure strong tumors. For extra info, go to www.beyondair.web.

See also  Texas Chief Admits Cops Made ‘Mistaken Choice’ To not Storm Uvalde Classroom

Ahead Trying Statements

Sure statements herein regarding the Firm’s future expectations, plans and prospects, together with with out limitation, the Firm’s present expectations relating to its enterprise technique, product candidates, and medical growth course of and timing, represent forward-looking statements. Using phrases comparable to “could,” “would possibly,” “will,” “ought to,” “anticipate,” “plan,” “anticipate,” “imagine,” “estimate,” “venture,” “intend,” “Future,” “potential,” or “proceed,” the detrimental of those and different related expressions are supposed to determine such ahead trying statements. Such statements, primarily based as they’re on the present expectations of administration, inherently contain quite a few dangers and uncertainties, identified and unknown, a lot of that are past the Firm’s management. Consequently, precise future outcomes could differ materially from the anticipated outcomes expressed in such statements. Within the case of forward-looking statements relating to investigative product candidates and persevering with additional growth efforts, particular dangers which may trigger precise outcomes to vary materially from the Firm’s present expectations embrace: scientific, regulatory and technical developments; failure to show security, tolerability and efficacy; last and high quality managed verification of knowledge and the associated analyzes; expense and uncertainty of acquiring regulatory approval, together with from the US Meals and Drug Administration; and the Firm’s reliance on third events, together with licensors and medical analysis organizations. Don’t place undue reliance on any forward-looking statements included herein, which converse solely as of the date hereof and which the Firm is underneath no obligation to replace or revise because of any occasion, circumstances or in any other case, until required by relevant legislation .


Matt Johnson, Head of Company Growth & Technique
Past Most cancers, Ltd
[email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
(212) 915-2577

Supply: Past Most cancers ™